Garuda Therapeutics has raised a $62M Series B funding round to develop curative therapies for over 120 diseases, including hematological and oncological diseases.

 

Garuda Therapeutics has raised a $62M Series B funding round to develop curative therapies for over 120 diseases, including hematological and oncological diseases.  The company is based in Boston, Massachusetts. Garuda Therapeutics is developing off-the-shelf hematopoietic stem cell therapies to treat hundreds of severe and life-threatening diseases. The company aims to eliminate the need for donor cells used in blood stem cell transplants. Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital led the funding round, with participation from Sectoral Asset Management. Since its inception in 2021, the company has raised $134M.